Pseudomonas Aeruginosa Infection Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.70 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Pseudomonas Aeruginosa Infection Treatment Market Analysis
The Pseudomonas aeruginosa infection treatment market is expected to register a CAGR of 4.7% during the forecast period.
The market expanded during COVID-19 because some of the patients who received COVID-19 therapy in hospitals and other healthcare institutions had pseudomonas aeruginosa infections as a result of the use of ventilators and other medical devices. According to the study published in Cell Reports in August 2021, it was found that Pseudomonas aeruginosa, a common coinfecting infection in COVID-19 patients, causes illness aggravation. Pseudomonas aeruginosa abundance increases with SARS-CoV-2 viral RNA load. Individuals infected with P. aeruginosa and suffering from COVID-19 pneumonia were given "oral ciprofloxacin" drug formulations. Thus, the studies demonstrated that COVID-19 had a favourable impact on the growth of the studied market. However, the COVID-19 infection cases have been subsidized currently, studied market is expected to project stable growth over the forecast period due to the rising burden of pseudomonas aeruginosa infection.
The major factors such as the increasing incidence of infections associated with it such as pneumonia, cystic fibrosis, and urinary tract infections, the increasing development of products, increasing antibacterial resistance, and growing R&D activities are driving the growth of the Pseudomonas aeruginosa infection market.
The prevalence of hospital-acquired infections has increased in recent years. According to an article published in the National Library of Medicine in August 2022, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 and 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases. As a result of the increased burden of P. aeruginosa infection, the demand for its treatment is predicted to rise over the projection period, thereby boosting the growth of the studied market.
Furthermore, growing research and development activities on pseudomonas aeruginosa infection are expected to support market expansion over the forecast period. For instance, according to ClinicalTrials.gov updated in October 2022, a study titled "A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa" is under phase II trials and expected to be completed by 2024. Thus, such a study is expected to bring an advanced product for treating pseudomonas aeruginosa infection, thereby boosting the market's growth.
Various organic and inorganic strategies by the market players are likely to support the growth of the market. For instance, in April 2021, UK-based Phico Therapeutics secured an initial USD 5.3 million grant from CARB-X for developing intravenous-engineered bacteriophage drugs to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Thus, all the aforementioned factors, such as the growing prevalence of pseudomonas aeruginosa infection and rising drug development and discovery activities, are expected to propel the growth of the market over the forecast period. However, drug resistance ability of pseudomonas aeruginosa may restraint the market growth over the forecast period.
Pseudomonas Aeruginosa Infection Treatment Market Trends
This section covers the major market trends shaping the Pseudomonas Aeruginosa Infection Treatment Market according to our research experts:
Combination Therapy is Expected to Hold a Significant Share Over the Forecast Period.
Combination therapy for the treatment of P. aeruginosa is administered due to different considerations - first, to cover the known or suspected pathogen while results of identification and susceptibility testing are pending; second, to avoid the emergence of resistance during treatment; and third, due to possible synergistic activity resulting in better clinical outcome.
According to an article published in Antibiotics in November 2021, antimicrobial susceptibility testing showed that P. aeruginosa strains were highly resistant to ceftazidime (88.9%) and cefepime (82.2%), which were the most prevalent among wound infections. Imipenem and amikacin were the most effective drugs with the least resistance percentage (28.9%). The research concluded that the drug combination viewed a statistically significant reduction in bacterial counts when receiving definite combination therapy, compared to monotherapy, and combination therapy showed good results.
Additionally, the rise in demand for combination therapy for the treatment of pseudomonas aeruginosa infection is attributed to the rapid onset of action, high bioavailability rate, cost saving, and high efficiency. Thus, due to the benefits of combination therapy over monotherapy, this segment is expected to grow during the forecast period.
North America is Expected to Hold a Significant Share Over the Forecast Period
North America is expected to hold a significant share owing to the increase in hospital stays due to chronic diseases and surgeries, the rising number of hospital admissions, the increasing burden of hospital-acquired infection coupled with the innovative technologies implemented in devices that control infection, and others.
An increase in hospital-acquired infections is expected to propel the growth of the studied market in the North America region. According to Statistics Canada in a report published in January 2022, each year, many Canadians acquire an infection during their hospital stay that increases morbidity and mortality, and that bears a financial cost to the healthcare system. Every year, it is estimated that 220,000 Canadian patients develop an HAI. Thus, a growing burden of hospital-acquired infection in Canada is expected to support the market expansion over the forecast period.
Additionally, the rise in chronic diseases such as cardiovascular diseases, cancer, and others requires extended hospital stays and surgeries. For instance, according to 2022 data from the American Health Association, there were approximately 33,356,853 hospital admissions in 2022. Many of these admissions were due to chronic diseases and critical procedures like heart bypass surgery. Thus, the increasing number of hospital admissions is expected to create a need for infection control products and thereby boost the market in the region.
Additionally, various strategies adopted by the market players, such as product launches, mergers, and acquisitions, are expected to propel the growth of the market. For instance, in May 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., launched its generic Erythromycin tablets in availble in 250 mg and 500 mg strengths, it is a therapeutic equivalent for Arbor Pharmaceuticals' reference listed drug (RLD) Erythromycin Tablets. Teva generic Erythromycin pills are used to treat a wide range of bacterial illnesses, including pneumonia.
Thus, the growing burden of hospital-acquired infection coupled with hospital admission is expected to boost the market growth in the North America region over the forecast period.
Pseudomonas Aeruginosa Infection Treatment Industry Overview
The pseudomonas aeruginosa infection treatment market is fragmented and consists of several players. The majority of the Pseudomonas aeruginosa infection treatment drugs and therapies are being manufactured by the global key players. Market leaders with more funds for research and better distribution systems have established their positions in the market. Some of the market players are Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc., Merck & Co Inc., AbbVie Inc. (Allergan)
Pseudomonas Aeruginosa Infection Treatment Market Leaders
-
Teva Pharmaceutical Industries Ltd
-
Johnson & Johnson
-
Pfizer Inc
-
Merck & Co Inc
-
AbbVie Inc. (Allergan)
*Disclaimer: Major Players sorted in no particular order
Pseudomonas Aeruginosa Infection Treatment Market News
- In December 2022, Clarametyx Biosciences has begun a Phase Ia clinical trial of CMTX-101, an immune-enabling antibody therapy, to treat community-acquired bacterial pneumonia.
- In March 2022, The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a roughly USD 2.5 million grant to two University of Maryland School of Pharmacy (UMSOP) staff members to examine how infections caused by the bacteria Pseudomonas aeruginosa develop multidrug resistance.
Pseudomonas Aeruginosa Infection Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Hospital-acquired Infections
- 4.2.2 Investment in Research and Drug Discovery for Pseudomonas Aeruginosa
-
4.3 Market Restraints
- 4.3.1 Drug Resistance Ability of Pseudomonas Aeruginosa
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 Treatment
- 5.1.1 Monotherapy
- 5.1.2 Combination Therapy
-
5.2 Route of Administration
- 5.2.1 Nasal
- 5.2.2 Oral
- 5.2.3 Intravenous
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc. (Allergan PLC)
- 6.1.2 Teva Pharmaceutical Industries Ltd
- 6.1.3 Pfizer Inc.
- 6.1.4 Lupin Pharmaceuticals Inc.
- 6.1.5 AstraZeneca PLC
- 6.1.6 Merck & Co. Inc.
- 6.1.7 Bristol Myers Squibb Company
- 6.1.8 Johnson & Johnson
- 6.1.9 Baxter International Inc.
- 6.1.10 Neopharma
- 6.1.11 CARB-X Company
- 6.1.12 Sanofi SA
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPseudomonas Aeruginosa Infection Treatment Industry Segmentation
As per the scope of the report, pseudomonas aeruginosa is a rod-shaped, encapsulated, Gram-negative bacteria that causes diseases in humans. It infects people with weakened immune systems causing 'blue-green pus bacteria' associated with hospital-acquired infections such as ventilator-associated pneumonia and sepsis. Pseudomonas aeruginosa infection treatment drugs inhibit the growth of Pseudomonas aeruginosa or completely eliminate the bacterium. The Pseudomonas Aeruginosa Infection Treatment Market is Segmented by Treatment (Monotherapy and Combination Therapy), Route of Administration (Nasal, Oral, and Intravenous), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for all the above segments.
| Treatment | Monotherapy | |
| Combination Therapy | ||
| Route of Administration | Nasal | |
| Oral | ||
| Intravenous | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Pseudomonas Aeruginosa Infection Treatment Market Research FAQs
What is the current Pseudomonas Aeruginosa Infection Treatment Market size?
The Pseudomonas Aeruginosa Infection Treatment Market is projected to register a CAGR of 4.70% during the forecast period (2024-2029)
Who are the key players in Pseudomonas Aeruginosa Infection Treatment Market?
Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc, Merck & Co Inc and AbbVie Inc. (Allergan) are the major companies operating in the Pseudomonas Aeruginosa Infection Treatment Market.
Which is the fastest growing region in Pseudomonas Aeruginosa Infection Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Pseudomonas Aeruginosa Infection Treatment Market?
In 2024, the North America accounts for the largest market share in Pseudomonas Aeruginosa Infection Treatment Market.
What years does this Pseudomonas Aeruginosa Infection Treatment Market cover?
The report covers the Pseudomonas Aeruginosa Infection Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Pseudomonas Aeruginosa Infection Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Pseudomonas Aeruginosa Treatment Industry Report
Statistics for the 2024 Pseudomonas Aeruginosa Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pseudomonas Aeruginosa Treatment analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
